phrykt

Envoy Medical, Inc. (COCH): who owns it and who trades it

As of Nov 16, 2026, COCH insiders reported 6 purchases worth $8.2M in the last 12 months. The largest buyer was Glen A Taylor (10% owner), with $7.5M. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Envoy Medical

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns COCH

32 funds and institutions reported COCH shares worth $19.9M at the end of Q2 2026, about 33% of the company. The largest holder is Nantahala Capital Management, LLC with 19.9%.

Funds and institutions (13F) 33%Everyone else 67%

10 largest owners, by share of the company

Nantahala Capital Management, LLC19.9%
Bleichroeder LP8.1%
Vanguard Capital Management LLC1.1%
DSG Capital Advisors, LLC0.8%
Geode Capital Management, LLC0.7%
Focus Partners Wealth0.6%
Vanguard Fiduciary Trust Co0.4%
UBS Group AG0.2%
Arcus Capital Partners, LLC0.2%
ExodusPoint Capital Management, LP0.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC15.30M19.90%$11.9M+100%
Bleichroeder LP6.25M8.13%$5MNo change
Vanguard Capital Management LLC880,2141.14%$697K-0%
DSG Capital Advisors, LLC625,0000.81%$474KNo change
Geode Capital Management, LLC541,7290.70%$429K+4%
Focus Partners Wealth425,3100.55%$337K+100%
Vanguard Fiduciary Trust Co296,6790.39%$235K+1%
UBS Group AG190,8380.25%$151K+171%
Arcus Capital Partners, LLC187,5730.24%$149KNo change
ExodusPoint Capital Management, LP182,3540.24%$144KNew
Northern Trust Corp109,4660.14%$86.7K-1%
Morgan Stanley90,9210.12%$72K+23%
CIBC Bancorp USA Inc.77,8870.10%$61.7KNo change
LPL Financial LLC48,4010.06%$38.3K+70%
Jane Street Group, LLC31,2230.04%$24.7KNew
Meteora Capital, LLC28,0510.04%$22.2KNo change
State Street Corp23,8720.03%$18.9KNo change
XTX Topco Ltd17,1460.02%$13.6KNew
Afg Fiduciary Services Limited Partnership12,0000.02%$9KNo change
BlueStem Wealth Partners, LLC10,4540.01%$8.3KNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, COCH insiders reported $8.2M of open-market purchases and $0 of sales.

Purchases, 12 months
$8.2M
6 trades, 6 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Feb 12, 2026
Filed Feb 17, 2026

Purchases and sales by month

$8.2M$8.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Feb 12, 2026Mona Chetan PatelDirectorPurchase312,500$0.40$125KForm 4
Feb 12, 2026Robert PotashnickCFOPurchase212,500$0.40$85KForm 4
Feb 12, 2026Susan KantorDirectorPurchase96,150$0.40$38.5KForm 4
Feb 12, 2026Charles BrynelsenDirectorPurchase1.00M$0.40$400KForm 4
Feb 12, 2026Brent T. LucasCEOPurchase62,500$0.40$25KForm 4
Feb 12, 2026Glen A Taylor10% ownerPurchase18.75M$0.40$7.5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Glen A Taylor10% owner$7.5M–Feb 12, 2026
Charles BrynelsenDirector$400K–Feb 12, 2026
Mona Chetan PatelDirector$125K–Feb 12, 2026
Robert PotashnickInterim CFO$85K–Feb 12, 2026
Susan KantorDirector$38.5K–Feb 12, 2026
Brent T. LucasChief Executive Officer, Director$25K–Feb 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

COCH short interest

Low short interest. 0.1% of COCH shares are sold short: about 1 share in 859. Over the last 12 reports the number of shares short went down 93%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 89,915 COCH shares were sold short, 0.1% of the shares outstanding, down 84.4% from the report before. At the average daily volume of 33,639 shares, buying them all back would take about 2.7 trading days (days to cover).

Shares short, % of all shares

0.12%May 15Oct 301.86%

Days to cover

2.7May 15Oct 3013.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202689,9150.12%-84%33,6392.7
Oct 15, 2026577,0870.75%+16%76,8117.5
Sep 30, 2026497,9690.65%-6%62,5338.0
Sep 15, 2026529,1300.69%-13%49,04510.8
Aug 31, 2026605,7980.78%-30%58,31010.4
Aug 14, 2026865,2481.12%-11%155,1615.6
Jul 31, 2026976,3381.27%+11%286,5123.4
Jul 15, 2026879,8861.14%-11%390,8722.2
Jun 30, 2026983,7621.28%-14%1.30M1.0
Jun 15, 20261.15M1.49%-1%127,0929.0
May 29, 20261.15M1.50%-8%132,6128.7
May 15, 20261.26M1.63%-7%108,99111.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Envoy Medical company events

Envoy Medical filed 21 reports on Form 8-K in the last 12 months, 9 of them about an important change (leadership, listing, auditor). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 27, 2026SharesChanged the rights of its shareholders. Filing
  3. Oct 16, 2026VoteReported shareholder vote results. Filing
  4. Oct 7, 2026AnnouncementEnvoy Medical, Inc., a Delaware corporation, entered into a Dismissal Agreement regarding litigation in the Delaware Court of Chancery with Atlas Merchant Capital SPAC Fund I LP related to Atlas’ allegation that it was not allowed to redeem its shares of Class A Common Stock in the Company’s… Filing
  5. Aug 27, 2026LeadershipEnvoy Medical, Inc. appointed Robert Potashnick to serve as the Company’s Chief Accounting Officer and Vice President of Finance. Filing
  6. Aug 10, 2026ResultsReleased financial results. Filing
  7. Jun 30, 2026AgreementEnded an important agreement. Filing
  8. Jun 25, 2026LeadershipThe Compensation Committee of the Board of Directors of Envoy Medical, Inc., approved certain changes to the compensation of the Company’s Chief Executive Officer, Brent Lucas. Filing
  9. May 22, 2026ListingAs previously disclosed, on November 19, 2025, Envoy Medical, Inc., received a staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC, informing the Company that its Class A Common Stock, par value $0.0001 per share, had failed to comply with the $1.00… Filing
  10. May 18, 2026LeadershipEnvoy Medical, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  11. May 11, 2026ResultsReleased financial results. Filing
  12. Apr 21, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Envoy Medical, Inc., the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company’s 2027 annual meeting of stockholders. Filing
  13. Mar 31, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  14. Mar 27, 2026ResultsReleased financial results. Filing
  15. Feb 27, 2026ListingEnvoy Medical, Inc. received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025. Filing
  16. Feb 13, 2026AgreementEnvoy Medical, Inc., a Delaware corporation, commenced a best efforts public offering of an aggregate of (i) 47,946,150 shares of the Company’s Class A Common Stock, par value $0.0001 per share, (ii) 27,053,850 pre-funded warrants to purchase 27,053,850 shares of Common Stock, (iii) 45,000,000… Filing
  17. Feb 11, 2026LeadershipThe Compensation Committee of the Board of Directors of Envoy Medical, Inc. approved the issuance of stock options to the Company’s Chief Executive Officer, Brent Lucas, and its Interim Chief Financial Officer, Robert Potashnick under the Company’s 2023 Equity Incentive Plan, as amended. Filing
  18. Dec 29, 2025AgreementEnvoy Medical, Inc. has previously issued Stock Purchase Warrants (as amended to date, the “ Shortfall Warrants ”) to Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP and Meteora Strategic Capital, LLC (“ MSC ” and, collectively… Filing
  19. Dec 16, 2025AnnouncementShared information with investors. Filing
  20. Dec 3, 2025VoteReported shareholder vote results. Filing
  21. Nov 25, 2025ListingEnvoy Medical, Inc. received a staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC, informing the Company that its Class A Common Stock, par value $0.0001 per share, has failed to comply with the $1.00 minimum bid price required for continued listing… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Envoy Medical financials

Famous investors that hold COCH

1 of the 50 well-known investors we track reported holding COCH in their latest 13F filing. The largest position is Ken Griffin's, worth $19.3K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202628,278$19.3K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Envoy Medical, Inc. (COCH) stock

Who owns the most COCH stock?

The largest reported owner of Envoy Medical, Inc. (COCH) is Nantahala Capital Management, LLC, with 19.9% of the company. In total, 32 funds and institutions reported holding COCH at the end of Q2 2026, together about 33% of the shares. See the largest owners.

Are COCH insiders buying or selling?

In the last 12 months, COCH insiders reported 6 open-market purchases worth $8.2M and no sales. The latest trade was on Feb 12, 2026. See every trade.

What is the short interest in COCH?

As of Oct 30, 2026, 89,915 COCH shares were sold short, 0.1% of the shares outstanding, down 84.4% from the report before. At the average daily volume of 33,639 shares, buying them all back would take about 2.7 trading days (days to cover). See the history.

Which famous investors hold COCH?

1 of the 50 well-known investors we track reported COCH in their latest 13F filing, including Ken Griffin. The largest position is worth $19.3K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.